TEL AVIV,
Israel, Oct. 30, 2023 /PRNewswire/ -- Chemomab
Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage
biotechnology company developing innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today announced
the company will release its third quarter 2023 financial results
and a business update on November 9,
2023 at 8:00 am Eastern
Time.
Investors who would like to discuss the financial
results or business update post-release are invited to contact the
company at IR@chemomab.com.
About Chemomab Therapeutics
Ltd.
Chemomab is a clinical stage biotechnology company
developing innovative therapeutics for fibro-inflammatory diseases
with high unmet need. Based on the unique and pivotal role of CCL24
in promoting fibrosis and inflammation, Chemomab developed CM-101,
a monoclonal antibody designed to neutralize CCL24 activity. In
preclinical and clinical studies, CM-101 appears safe, with the
potential to treat multiple severe and life-threatening
fibro-inflammatory diseases. Chemomab has reported encouraging
results from three clinical trials of CM-101 in patients, including
a Phase 1b trial in NAFLD patients, a
Phase 2a liver fibrosis trial in NASH patients and an
investigator-initiated study in patients with severe lung injury.
The CM-101 program for the treatment of systemic sclerosis is Phase
2-ready and a Phase 2 trial in primary sclerosing cholangitis
patients is ongoing, with topline data expected in the second half
of 2024. For more information about Chemomab, visit
chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-report-third-quarter-2023-financial-results-and-provide-a-business-update-301970948.html
SOURCE Chemomab Therapeutics